Stocksigma LogoStocksigma Logo

Remus Pharma Approves Main Board Migration, Dominican Subsidiary, and Director Appointment

On 2nd Sep'26, Remus Pharmaceuticals approved its migration from the NSE Emerge platform to the NSE and BSE Main Boards, subject to shareholder and

Remus Pharma Approves Main Board Migration, Dominican Subsidiary, and Director Appointment

Remus Pharmaceuticals Ltd 路 Outcome 路 02 Sept 2026, 11:59 pm

Remus Pharma Approves Main Board Migration, Dominican Subsidiary, and Director Appointment On 2nd Sep'26, Remus Pharmaceuticals approved its migration from the NSE Emerge platform to the NSE and BSE Main Boards, subject to shareholder and regulatory approvals. The Board also authorized incorporating a pharmaceutical distribution subsidiary in the Dominican Republic to support global expansion, with Remus acquiring a 51%+ stake via cash consideration. Furthermore, entrepreneur Ashutosh Valani was appointed as a Non-Executive Independent Director for a five-year term to strengthen corporate governance and strategic oversight.

Original exchange filing (PDF)

More announcements from Remus Pharmaceuticals Ltd

All Remus Pharmaceuticals Ltd announcements